Project Name: Service improvement for the detection and treatment of Heart Failure (“HF”) in secondary care (“Integrated Nurse Programme”)
Project Summary:
The primary aim is to improve the identification, management and outcomes of Acute Decompensated Heart Failure (ADHF) patients with improved delivery of evidence based HF drug therapies, and to reliably provide early post discharge review and transition to the community HFSN team. This may reduce length of stay and is expected to reduce re-admissions and improve prognosis. Additionally, the project aims at establishing a case for future funding of the HF service by the project partner to continue the level of service established in this 12 month (clinical activity) project.
Planned Milestones:
- Collection of baseline data, in line with the above Project Outcome Measures & Data Collection table
- Confirmation of recruitment of Band 6 Nurse Specialist
- Confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity (CW Partner shall ensure that the clinical staff covered by the Novartis Financial Contribution are in place, trained and ready to begin clinical activity).
- Collection & submission of 3 months clinical activity data; Project Review meeting to discuss project progress.
- Collection & submission of 6 months clinical activity data; Project Review meeting to discuss project progress.
- Collection & submission of 9 months clinical activity data; Project Review meeting to discuss project progress.
- Collection & submission of 12 months clinical activity data; Project Review meeting to discuss project progress.
- Development of business case
- Submission of business case by the CW Partner HF team to relevant body within the NHS Board
- Submit final CWP report to Novartis within 3 months completion of the clinical work
Expected Benefits:
Anticipated benefits for patients:
Improved access to optimal diagnosis and treatment;
More equitable and consistent care and access to care; and
Enhanced experience for HF patients and carers who live with HF due to access to HF specialist service
Anticipated benefits for the organisation:
Increased overall quality of care and improve equity of access to specialist care for patients with HF.
Improved patient flow and reduced total number of inpatient bed days due to HF;
Increased proportion of patients with HF being managed in accordance with NICE guideline standards; and
Insight into benefits of an inpatient HF service which may inform ongoing redesign and workforce planning.
Anticipated benefits for Novartis:
Further opportunities for the appropriate use of cardiology licensed medicines in line with NICE guidelines, including Novartis’s medicine.
Improved reputation.
Improved professional and transparent relationship and trust between Novartis and the NHS.
Start Date & Duration:
Start date: September
Duration: 15 months
UK2308293229